📊 CV Key Takeaways
Investment Thesis
CapsoVision is a financially distressed medical device company with severe operational losses that far exceed revenues, negative free cash flow of -$15.3M, and deteriorating profitability. Despite healthy balance sheet liquidity metrics, the company is burning cash at an unsustainable rate with operating losses exceeding 180% of revenue, indicating fundamental business model challenges or failed commercialization efforts.
CV Strengths
- Solid current ratio of 5.19x and quick ratio of 4.50x indicating near-term liquidity is not an immediate concern
- Gross margin of 54.2% suggests products have reasonable unit economics when sold
- Minimal debt burden with 0.00x debt-to-equity ratio providing some financial flexibility
CV Risks
- Severe operating losses of -$18.1M on only $9.6M revenue demonstrates inability to control operating expenses or achieve necessary scale
- Negative free cash flow of -$15.3M annually is unsustainable and indicates ongoing cash burn that will deplete equity reserves
- Negative net margin of -186% and negative ROE of -87.7% reveal fundamental unprofitability with no clear path to breakeven
- Operating cash flow of -$15.2M mirrors free cash flow, indicating losses are actual cash outflows not accounting adjustments
Key Metrics to Watch
- Revenue growth rate and ability to reach scale that justifies current operating cost structure
- Operating expense reduction initiatives and timeline to operating break-even
- Quarterly cash burn rate and cash runway remaining before liquidity crisis
- Gross margin trends to confirm products remain economically viable
CV Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 5.19x current ratio provides a solid financial cushion.
CV Profitability Ratios
CV vs Healthcare Sector
How CapsoVision, Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CV Balance Sheet & Liquidity
CV Growth Metrics (YoY)
CV Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $3.0M | -$4.2M | $-0.17 |
| Q2 2025 | $2.8M | -$4.2M | $-2.02 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CV Capital Allocation
CV SEC Filings
Access official SEC EDGAR filings for CapsoVision, Inc (CIK: 0001378325)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CV
What is the AI rating for CV?
CapsoVision, Inc (CV) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CV's key strengths?
Solid current ratio of 5.19x and quick ratio of 4.50x indicating near-term liquidity is not an immediate concern. Gross margin of 54.2% suggests products have reasonable unit economics when sold.
What are the risks of investing in CV?
Severe operating losses of -$18.1M on only $9.6M revenue demonstrates inability to control operating expenses or achieve necessary scale. Negative free cash flow of -$15.3M annually is unsustainable and indicates ongoing cash burn that will deplete equity reserves.
What is CV's revenue and growth?
CapsoVision, Inc reported revenue of $9.6M.
Does CV pay dividends?
CapsoVision, Inc does not currently pay dividends.
Where can I find CV SEC filings?
Official SEC filings for CapsoVision, Inc (CIK: 0001378325) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CV's EPS?
CapsoVision, Inc has a diluted EPS of $-1.05.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.